The hepatocyte growth factor/MET pathway has been shown to cause tumor progression in several types of carcinomas. The aim of this study was to examine the correlations between c-MET/phospho-MET expression as well as MET gene copy number alterations and overall survival (OS) in non-small cell lung carcinomas (NSCLCs). Methods: We analyzed 906 NSCLCs including 704 adenocarcinomas (ADCs), 150 squamous cell carcinomas (SCCs), 43 sarcomatoid carcinomas, and 9 large cell carcinomas. The mutational status of epidermal growth factor receptor and K-ras and anaplastic lymphoma kinase rearrangements were retrospectively examined. We performed immunohistochemistry to detect c-MET/phospho-MET expression and MET gene copy number using bright-field in situ hybridization (BISH). Results: c-MET/phospho-MET expression and MET BISH positivity were observed in 22.2%, 5.6%, and 10.9% of NSCLCs, respectively; they were more prevalent in ADCs (27.3%, 6.9%, and 11.5%, respectively) and sarcomatoid carcinomas (20.9%, 9.3%, and 36.6%, respectively) than in SCCs and large cell carcinomas. Among ADCs, poorly differentiated cases exhibited c-MET expression and MET BISH positivity more commonly than well-differentiated ones. An analysis of all patients revealed that c-MET/phospho-MET expression and MET BISH positivity were not correlated with OS. However, when SCC cases were excluded, both univariate (p ϭ 0.019) and multivariate (p ϭ 0.020) analyses revealed a significant correlation between MET BISH positivity and OS. Conclusions: c-MET/phospho-MET expression and MET BISH positivity differed according to histological type. Among ADCs, c-MET expression and MET BISH positivity were more common in poorly differentiated cases. MET BISH positivity was an independent prognostic factor in nonsquamous NSCLCs.
T he c-MET is a high-affinity receptor for hepatocyte growth factor (HGF), a disulfide-linked heterodimeric molecule mainly produced by mesenchymal cells. 1,2 HGF binds to c-MET receptor and undergoes phosphorylation on intracellular tyrosine residues, which leads to the activation of downstream signaling. 2 Among these tyrosine residues, Tyr1234/1235 is one of the major phosphorylation sites. Signaling through the HGF/MET pathway results in tumor growth, angiogenesis, and the development of invasive phenotypes in several types of malignancy, making this pathway an attractive target for potential treatment. 3 In lung cancers, c-MET protein is reportedly expressed in up to 70% of adenocarcinomas (ADCs) and 40% of squamous cell carcinomas (SCCs); it is also associated with advanced tumor stage and poor clinical outcome. 4 -6 Similar to c-MET protein expression, MET gene amplification is an independent unfavorable prognostic factor in surgically resected non-small cell lung carcinomas (NSCLCs). 7, 8 In addition, MET gene amplification is reported to be associated with 20% of lung ADCs with acquired resistance against epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI). 9, 10 MET gene amplification has been analyzed in NSCLCs by various assays including real-time polymerase chain reaction, comparative genomic hybridization, and fluorescence in situ hybridization (FISH); its frequency is reported to range from 1.1 to 21%. 7, 8, [11] [12] [13] [14] Among these methods, FISH is considered the standard method for assessing gene copy number. However, the main disadvantage of FISH is that the fluorescent signals fade over time. Recently, bright-field in situ hybridization (BISH) was tested as an emerging alternative method for assessing gene copy number alterations of various genes including human epidermal growth factor 2 (HER2) 15 and EGFR. The advantage of BISH is that it enables the evaluation of slides by light microscopy, which allows the simultaneous visualization of amplified signals and cell morphology.
In this study, we analyzed the expression of c-MET and phospho-MET (Tyr1234/1235) by immunohistochemistry and MET gene copy number alterations by BISH. We also analyzed the correlations between c-MET/phospho-MET ex-pression and MET gene copy number alterations, the clinicopathological parameters including the status of EGFR and K-ras mutations, and the anaplastic lymphoma kinase (ALK) rearrangements.
PATIENTS AND METHODS

Case Selection
The institutional review board approved the study. The specimens used in this study were from 906 patients who underwent lung resection for ADC, SCC, large cell carcinoma (LCC), or sarcomatoid carcinoma (SAC) at the National Cancer Center Hospital (Tokyo, Japan) from 1997 to 2007. Histological diagnosis was based on the scheme of the latest World Health Organization classification 16 with the aid of immunohistochemical panels. 17 Furthermore, ADC and SCC cases were graded on the basis of differentiation in a three-tiered system. For ADC, well-differentiated tumors were consistent with predominant lepidic or papillary patterns, moderately differentiated tumors were consistent with a predominant acinar pattern, and poorly differentiated tumors were consistent with a solid growth pattern. For SCC, welldifferentiated tumors had an obvious stratified pattern, various uniform or slight pleomorphic nuclei, and significant keratinization; moderately differentiated tumors had a stratified pattern, although the degree of stratification and keratinization was lower than that of the well-differentiated tumors; poorly differentiated tumors primarily exhibited solid growth and only had focal-stratified patterns and keratinization.
We collected the patients' age, gender, smoking history, treatment modalities, outcomes, maximum tumor size (in centimeter), and pathologic stage (p-stage). Staging was based on the guidelines of the seventh edition of the tumor, node, metastasis classification for lung cancer. 18 
Microarray Construction
The most representative tumor areas were sampled for tissue microarray. The tissue microarrays were assembled with a tissue-arraying instrument KIN-1 (Azumaya, Tokyo, Japan). To reduce sampling bias due to tumor heterogeneity, we used duplicate core samples measuring 2.0 mm in diameter taken from two different portions of a tumor.
Immunohistochemistry
For c-MET immunohistochemical staining, the BenchMark XT automated slide processing system (Ventana, Tucson, AZ) was used according to the manufacturer's protocol. In brief, after the tissue sections were deparaffinized using EZ Prep (Ventana), heat-induced epitope retrieval with CC1 (Ventana) was performed, and the slides were incubated with primary antibodies against c-MET (CONFIRM Anti-Total c-MET, clone SP44; Ventana). Immunoreactions were detected using the ultraView DAB Universal Detection Kit followed by counterstaining with Hematoxylin II (Ventana) and Bluing Reagent (Ventana). For phospho-MET (Tyr1234/1235) immunohistochemical staining, heat-induced epitope retrieval with Target Retrieval Solution (pH 9.0) (Dako Corporation, Carpinteria, CA) was performed. The slides were subsequently incubated with primary antibodies against phospho-MET (1:200, D26; Cell Signaling Technology, Danvers, MA) for 1 hour at room temperature. Immunoreactions were detected using the EnvisonPlus system (Dako Corporation), visualized with 3,3-diaminobenzidine, and then counterstained with hematoxylin. For c-MET, immunopositive cases were defined as those exhibiting cytoplasmic and/or membranous staining in Ն10% of cells ( Figure 1A ). For phospho-MET, immunopositive cases were defined as those exhibiting membranous staining in Ն10% of cells.
BISH Analysis
The dual-color BISH assay for MET and chromosome 7 centromere (CEN7) DNA targets was performed using a sequential hybridization method 15 on the BenchMark XT system (Ventana). In brief, after deparaffinization using EZ Prep (Ventana), the tissue sections were subjected to heatinduced target retrieval using CC2 (Ventana) and digested with in situ hybridization (ISH) Protease 3 (Ventana). Then, the tissue samples were hybridized with INFORM MET DNA Probe (Ventana), a dinitrophenyl-labeled nick-translated repeat-deleted DNA probe, for 6 hours. After stringency washes with 2ϫ saline-sodium citrate buffer (Ventana), MET probe hybridization sites were visualized with ultraView silver in situ hybridization detection kit (Ventana). For CEN7 detection, the tissue sections were hybridized with INFORM Chromosome 7 Probe (Ventana), a dinitrophenyl-labeled oligoprobe, for 2 hours. The CEN7 ISH signal was detected with the ultraView Red ISH detection kit. Counterstaining was performed using Hematoxylin II (Ventana) and Bluing Reagent (Ventana).
We evaluated the BISH signals for each locus-specific BISH probe at 400ϫ and 600ϫ magnification using an Olympus BX50 microscope (Olympus, Tokyo, Japan). The copy number per cell was counted in 50 nonoverlapping tumor cell nuclei. On the basis of the International Union Against Cancer criteria for EGFR, 19 tumors were classified into two groups-BISH positive and BISH negative-according to the frequency of tumor cells with specific copy numbers of the MET gene and CEN7. A BISH-positive tumor was defined as a tumor meeting one of the five categories of MET gene status: MET gene amplification (MET to CEN7 ratio Ն2, Ͼ15 copies of the MET signal in Ͼ10% of tumor cells, small gene clusters [4 -10 copies each] in Ͼ10% the tumor cells, or innumerable tight gene clusters in Ͼ10% the tumor cells) and high polysomy (Ն40% of cells exhibiting Ն4 copies of the MET signal). Otherwise, the tumor was defined as BISH negative.
Analysis of EGFR and K-ras Mutational Status, ALK Rearrangement, and EGFR-TKI Response
We detected two common EGFR mutations (deletions in exon 19 [DEL] and a point mutation at codon 858 in exon 21 [L858R]) and K-ras mutations (in exons 1 and 2) using a high-resolution melting analysis routinely performed at our institution. 20 Echinoderm microtubule-associated protein-like 4 (EML4) and ALK fusions were analyzed by immunohistochemistry, reverse-transcriptase polymerase chain reaction, and/or BISH assay. Of the 906 cases, 110 received systemic therapy with EGFR-TKI gefitinib (250 mg daily) after tumor relapse or because of advanced stage. The clinical response to gefitinib was determined according to the Response Evaluation Criteria in Solid Tumors. 21 In this study, the complete response and partial response cases were categorized as responders, whereas the stable disease and progressive disease cases were categorized as nonresponders.
Statistical Analysis
Statistical analysis was performed using SPSS 12.0 for Windows (SPSS, Chicago, IL). Student t test and the 2 test were used for continuous and categorical variables, respectively. Progression-free survival and overall survival (OS) curves were calculated using the Kaplan-Meier method. The curves were compared using the log-rank test. Univariate survival analysis was performed with log-rank test and Cox's proportional hazard regression. In the multivariate Cox model, variables with p value less than 0.10 from Wald's test for univariate models were included. Statistical significance was set at p less than 0.05.
RESULTS
Clinicopathologic Background
A total of 906 cases were included as follows: 704 ADCs (291 well differentiated, 275 moderately differentiated, and 138 poorly differentiated histology), 150 SCCs (53 well differentiated, 51 moderately differentiated, and 46 poorly differentiated histology), 9 LCCs, and 43 SACs. There were 332 women and 574 men. The patients' mean age at the time of diagnosis was 61.7 years (range, 30 -88 years). Regarding smoking status, 416 were never-smokers and 490 were smokers. Tumor sizes ranged from 0.5 to 15.5 cm (mean, 3.53 cm). Lymph node status was recorded in 890 cases, and metastasis was present in 358. Regarding p-stage, 432, 226, 218, and 22 cases were at p-stages I, II, III, and IV, respectively. The mean and median follow-up times for all 906 patients was 53.3 months (range, 0.3-150 months) and 50.3 months, respectively, with 559 still alive (mean and median follow-up times were 66.5 and 61.3 months, respectively).
c-MET and Phospho-MET Protein Expression by Immunohistochemistry
c-MET expression was observed in 196 (22.2%) of 883 NSCLCs ( Figures 1A, B) . The c-MET-positive cases were significantly correlated with a histological subtype (p Ͻ 0.001): 186 (27.3%) of 682 ADCs, 1 (0.7%) of 149 SCCs, 0 (0%) of 9 LCCs, and 9 (20.9%) of 43 SACs. In ADCs, c-MET-positive cases were significantly correlated with histological grade (p ϭ 0.002): 32 (11.6%) of 276 with welldifferentiated, 42 (15.6%) of 270 with moderately differentiated, and 34 (25.2%) of 135 with poorly differentiated histology. c-MET-positive tumors were more common in younger patients (p ϭ 0.009) and were smaller (p ϭ 0.001) than c-MET-negative tumors (Table 1) . c-MET expression was not associated with gender, lymph node status, p-stage, EGFR or K-ras mutational status, or ALK rearrangements.
Phospho-MET expression was observed in 51 (5.8%) of 880 NSCLCs. The phospho-MET-positive cases were significantly correlated with the histological subtype (p ϭ 0.006): 47 (6.9%) of 678 ADCs, 0 (0%) of 150 SCCs, 0 (0%) of 9 LCCs, and 4 (9.3%) of 43 SACs. In contrast to c-MET expression in ADCs, phospho-MET expression was not associated with histological grade (p ϭ 0.726): 17 (6.1%) of 277 with well-differentiated, 21 (7.9%) of 267 with moderately differentiated, and 9 (6.7%) of 134 with poorly differentiated histology. Phospho-MET-positive tumors were more common in never-smokers (p ϭ 0.013) and smaller (p ϭ 0.001) than phospho-MET-negative tumors (Table 1) . Phospho-MET expression was not associated with gender, age, lymph node status, p-stage, EGFR or K-ras mutational status, or ALK rearrangements (Table 1) .
There was a significant association between c-MET and phospho-MET expression among the 864 cases for which both c-MET and phospho-MET data were available (p Ͻ 0.001). However, only 34 (30.1%) of 113 cases exhibited dual positivity.
MET BISH-Positive Cases
Of all NSCLCs, 92 (10.9%) of 844 cases were MET BISH-positive ( Figure 2 
Association between MET Status and EGFR-TKI Response
Among the 109 patients who received systemic therapy with EGFR-TKI gefitinib, the therapeutic effect of gefitinib was complete response in 3 patients, partial response in 53 patients, stable disease in 15 patients, and progressive disease in 38 patients. The background data of these 109 patients are as follows: 50 women and 59 men, 74 never-smokers and 35 former or present smokers, 108 ADCs and 1 SAC, 74 EGFR mutated and 35 wild type, and 3 K-ras mutated and 64 wild type. Among them, only EGFR mutational status was correlated with EGFR-TKI response (p Ͻ 0.001).
The expression of c-MET and phospho-MET was observed in 13 (24.1%) of 54 responders and 7 (7.7%) of 52 responders, respectively; MET BISH positivity was observed in 4 (8.3%) of 48 responders. No significant correlation was observed between c-MET/phospho-MET expression or MET BISH positivity and EGFR-TKI response.
In a univariate analysis of the patients who received systemic therapy with EGFR-TKI gefitinib, c-MET expression (hazard ratio 
Association between MET BISH Positivity and c-MET/Phospho-MET Protein Expression
A statistically significant association between c-MET expression and MET BISH positivity was found among the 830 cases for which both c-MET immunohistochemistry and BISH data were available ( Table 2 , p Ͻ 0.001). However, the frequency of dual positivity was not high: only 55 (28.8%) of 191 c-MET-positive cases were MET BISH positive.
A statistically significant association between phospho-MET and MET BISH positivity was found among the 824 cases for which both phospho-MET immunohistochemistry and BISH data were available ( Table 2 
Survival Analysis
To investigate the prognostic importance of c-MET/ phospho-MET expression and MET BISH positivity, the univariate and multivariate survival analyses were performed using the Cox proportional hazard model; the variables included gender, smoking history, lymph node status, p-stage, (Table 3) . Among nonsquamous NSCLCs, male gender (HR ϭ 1.5148, 95% CI ϭ 1.125-1.864; p ϭ 0.004), former/present smoking history (HR ϭ 1.460, 95% CI ϭ 1.145-1.861; p ϭ 0.002), lymph node metastasis (HR ϭ 4.024, 95% CI ϭ 3.102-4.024; p Ͻ 0.001), advanced p-stage (III or IV) (HR ϭ 3.276, 95% CI ϭ 2.565-4.184; p Ͻ 0.001), and MET BISH positivity ( Figure 3 ) (HR ϭ 1.508, 95% CI ϭ 1.066 -2.134; p ϭ 0.020) were significantly associated with a higher risk of death (Table  3) . Multivariate analysis of nonsquamous NSCLCs revealed that lymph node metastasis (HR ϭ 3.030, 95% CI ϭ 2.158 -4.255; p Ͻ 0.001), advanced p-stage (III or IV) (HR ϭ 1.625, 95% CI ϭ 1.183-2.233; p ϭ 0.003), and MET BISH positivity (HR ϭ 1.544, 95% CI ϭ 1.083-2.202; p ϭ 0.016) were independent prognostic factors ( Table 4) .
When analyzing advanced-stage disease in all patients, c-MET expression (HR ϭ 1.099, 95% CI ϭ 0.744 -1.622; p ϭ 0.637), phospho-MET expression (HR ϭ 1.165, 95% CI ϭ 0.593-2.289; p ϭ 0.657), and MET BISH positivity (HR ϭ 1.468, 95% CI ϭ 0.911-2.365; p ϭ 0.115) were not correlated with OS.
DISCUSSION
This study is one of the largest studies exploring the roles of c-MET/phospho-MET expression and MET gene copy number using the novel technology BISH in surgically resected NSCLCs naive to EGFR-TKIs. c-MET/phospho-MET expression and MET BISH positivity in NSCLCs were observed in 22.2%, 5.6%, and 10.9% of cases, respectively. They were more common in ADCs (27.3%, 6.9%, and 11.5%, respectively) and SACs (20.9%, 9.3%, and 36.6%, respectively) than in SCCs and LCCs.
Most studies analyzing c-MET expression by immunohistochemistry only include ADC histology; reported expression rates ranged between 24.0% and 74.6%. 6, [22] [23] [24] The possible reasons for this wide range are the application of different antibodies and/or different scoring methods. In this study, we used an SP44 clone to recognize the carboxyl domain of the transmembrane domain. In addition, our threshold of c-MET positivity was set at strong cytoplasmic and/or membranous staining Ն10% of cells, which may be more strict than that in previous studies. Consistent with other reports, our analysis of NSCLCs revealed that c-MET expression is more common in ADCs than in SCCs. 4, 22 Phospho-MET expression was observed in 51 (5.8%) of 880 NSCLCs and was more common in ADCs (6.9%) and SACs (9.3%). The phospho-MET expression rate in ADCs ranges from 7.0 to 21.5% in the previous reports. 6, 25 We found that c-MET expression was significantly correlated with phospho-MET expression. However, not all c-METpositive cases were phospho-MET positive and vice versa; this is possible because there are several different mechanisms of c-MET and phospho-MET activations. 26 The overexpression of c-MET alone does not seem to be sufficient to activate c-MET (phospho-MET expression) cascades. MET may also be activated by MET gene mutations.
The present MET BISH positivity rate of 10.9% in NSCLCs is within the range of previously reported MET gene amplification rates (1.1-21%). 7, 8, [11] [12] [13] [14] 25, 27 Consistent with some of the previous studies, our results show that MET BISH positivity was more common in ADCs than in SCCs. 12 In contrast to our results, Go et al. 14 report that MET amplification is more common in patients with SCC than in those with ADC. Okuda et al. 7 did not observe any correlation between MET amplification and the histological type of lung cancers. We found that in addition to MET BISH positivity, the expression of MET gene products, namely, c-MET/phos- pho-MET, was correlated with histological type. Another possible reason for this is accuracy of the histological diagnosis as it can be difficult to distinguish between the structure of poorly differentiated ADCs and SCCs; low interobserver agreement occurs even among experienced lung pathologists. 28 In our cohort, especially in poorly differentiated NSCLCs, histological typing was confirmed by using immunohistochemical markers. 17 These results indicate that c-MET expression and MET gene amplification are differentiation markers between ADCs and SCCs. Poorly differentiated ADCs more commonly exhibit c-MET expression and MET gene amplification than welldifferentiated ones. Similar to previous reports, moderately or poorly differentiated ADCs exhibited higher stages. However, there were no significant differences between p-stage and c-MET/phospho-MET expression or MET BISH positivity. These results may indicate that MET cascades affect tumor differentiation rather than tumor progression. In contrast to our results, other groups report that c-MET immunoreactivity is correlated with well-differentiated histology. 6, 22 Paradoxically, c-MET expression is also reported to be associated with advanced tumor stage and poor clinical outcomes. 4 -6 The results of the present and previous studies indicate that MET gene amplification is more prevalent in poorly differentiated ADCs than in well-differentiated ones. 8 We also frequently detected c-MET/phospho-MET expression and MET BISH positivity in SACs. There are no accounts regarding c-MET expression and MET gene amplification in pulmonary SACs. Other researchers have grouped SACs with LCCs/undifferentiated carcinomas or other types for analysis. In fact, Tsao et al. 22 observed c-MET protein expression in 21% of large/undifferentiated carcinomas before the publication of the World Health Organization third edition guidelines in which SAC was defined as an independent histological type for the first time. 29 Although SACs are smoking-related carcinomas, phospho-MET-positive tumors were more common in never-smokers (p ϭ 0.013), and c-MET expression and MET BISH positivity were not correlated with smoking status. In addition, SACs were usually more than 5 cm, and c-MET/phospho-MET-positive tumors were smaller (p ϭ 0.001) than c-MET/phospho-MET-negative tumors. c-MET is considered to be an epithelial-mesenchymal transition promoter that acts through Src activation. Epithelial-mesenchymal transition, a process essential to embryonic gastrulation, is proposed as a histogenetic mechanism for the anaplasia of undifferentiated carcinomas or SACs. 30 This is because 24 to 56% of SACs originate from ADCs, 31 and both the epithelial and sarcomatoid components of SACs originate from a single clone. 32 c-MET alterations seem to cause the conversion of ADCs to mesenchyme-like cells.
The present survival analysis indicates that c-MET/ phospho-MET expression and MET BISH positivity are not correlated with OS in NSCLC cases. However, when analyzing nonsquamous NSCLCs, MET BISH positivity was significantly correlated with OS. In addition, the multivariate analysis revealed that MET BISH positivity was an independent prognostic factor. Similar to our results, other researchers report that MET amplification is not correlated with unfavorable outcomes in NSCLC cases. 11, 13, 14 However, an analysis of ADCs alone indicates that MET gene amplification is correlated with unfavorable outcomes. 11 Meanwhile, other groups report a correlation between MET gene amplification and unfavorable outcomes in NSCLCs. 8 The main reasons for this seem to be due to the differences regarding methods, interpretation criteria, and patient cohorts, especially with respect to the proportion of poorly differentiated ADCs.
c-MET/phospho-MET expression and MET BISH positivity were not associated with EGFR or K-ras mutations or ALK rearrangements; these findings are not mutually exclusive. Previous reports indicate that MET amplification is correlated with acquired EGFR-TKI resistance. 9,27 However, we did not find a correlation between MET BISH positivity and primary EGFR-TKI resistance. One of the reasons why we did not find a correlation might be the fact that we analyzed primary EGFR-TKI resistance and not acquired resistance. More recently, Wu et al. 33 reported that MET gene amplification status is not predictive of the efficacy of first-line EGFR-TKI therapy. In addition, comparing the ratio of MET-amplified cases between EGFR-TKI-naive NSCLC and EGFR-TKI-resistant cell line models, Engelman et al. 9 suggest that MET gene amplification only plays a limited role in primary resistance to EGFR-TKI. On the other hand, Turke et al. 34 report that the existence of a subpopulation of MET-amplified cells before drug exposure and HGF accelerate the development of EGFR-TKI resistance through MET amplification.
In summary, c-MET/phospho-MET expression and MET BISH positivity were detected in 22.2%, 5.6%, and 10.9% of NSCLC cases, respectively. MET BISH positivity and c-MET/phospho-MET expression were significantly correlated with the histological type, especially ADCs and SACs, and were more prevalent in poorly differentiated ADCs. MET BISH positivity is an independent prognostic factor in nonsquamous NSCLCs. 
